Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850491 | 0.85 | FTO (0.60) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL6685820 | 0.84 | FTO (0.53) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL2409136 | 0.84 | FTO (0.55) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL20832 | 0.83 | ALDH1A1 (0.60) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL2407192 | 0.82 | FTO (0.59) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL3730178 | 0.82 | FTO (0.59) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL9427960 | 0.82 | FTO (0.59) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL23749241 | 0.82 | FTO (0.53) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL6248294 | 0.82 | FTO (0.53) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL5555251 | 0.82 | FTO (0.55) | FTOMAPTHPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098024-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-116840474-A | Device and method for cell secretion analysis | 不列颠哥伦比亚大学 | 2023-10-03 | — | — | CN | disclosed |
| CN-109154017-B | Device and method for cell secretion analysis | 不列颠哥伦比亚大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | IOVANCE BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | IOVANCE BIOTHERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3931310-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | Iovance Biotherapeutics, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2020210843-A9 | TOLEROGENIC ARTIFICIAL ANTIGEN-PRESENTING CELLS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020210843-A2 | TOLEROGENIC ARTIFICIAL ANTIGEN-PRESENTING CELLS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10695427-B2 | Shape memory particles for biomedical uses | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180140702-A1 | SHAPE MEMORY PARTICLES FOR BIOMEDICAL USES | UNIV JOHNS HOPKINS (US) | 2018-05-24 | — | — | US | disclosed |
| EP-3280761-A1 | SHAPE MEMORY PARTICLES FOR BIOMEDICAL USES | The Johns Hopkins University (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016164458-A1 | SHAPE MEMORY PARTICLES FOR BIOMEDICAL USES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | CD47, LTK, PBK | FTO 2337/4885MAPT 3478/4885HPGD 4493/4885 |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | PBK, LTK, CD47 | FTO 2780/4885MAPT 4189/4885HPGD 4364/4885 |
| US-10695427-B2 | Shape memory particles for biomedical uses | HIF1AN, HIF1A, HYOU1 | FTO 4653/4885MAPT 215/4885HPGD 485/4885 |
| US-20180140702-A1 | SHAPE MEMORY PARTICLES FOR BIOMEDICAL USES | HIF1AN, HIF1A, HYOU1 | FTO 4653/4885MAPT 215/4885HPGD 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.